Results of Type C Guidance Meeting with Food & Drug Administration (FDA) of ZYDIS® ODT Fluoxetine in the Treatment of Repetitive Behaviors in Autism
Autism Therapeutics LLC ("Autism Therapeutics") announced today that the Type C Guidance Meeting with FDA to discuss the ZYDIS® ODT Fluoxetine / Autism program has taken place. The FDA and Autism Therapeutics discussed the completion of the Phase III development of the program... - October 09, 2012
Press Releases 1 - 1 of 1